EDIT vs NTLA
EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases. NTLA: Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases.
Side-by-side fundamentals
| Metric | EDIT | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.84 | $12.60 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $436M | $1.8B | |
| Net margin FY2025, SEC XBRL | -395.0% | -609.9% | EDIT higher |
| Operating margin FY2025, SEC XBRL | -394.9% | -651.7% | EDIT higher |
| ROE FY2025, SEC XBRL | -586.6% | -61.5% | NTLA higher |
| ROA FY2025, SEC XBRL | -85.8% | -49.0% | NTLA higher |
| Debt / equity as of 2026-09-03 | 0.53 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-09-03 | +20.8% | +12.6% | EDIT higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | +9.1% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.23 | 1.66 | |
| 1-year return as of 2026-10-08 close | -31.6% | -48.5% | EDIT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.